Skip to content
This is a randomised controlled trial aimed to determine if maternal immunisation with 23 valent pneumococcal polysaccharide vaccine (23vPPV) can reduce pneumococcal carriage and middle ear disease among Aboriginal infants at seven months of age. The trial aims to recruit 210 Aboriginal women aged 18-39 years who have uncomplicated pregnancies: 70 will receive 23vPPV during the third trimester of pregnancy, 70 immediately postpartum, and 70 will act as a control group, receiving 23vPPV seven months after child birth. Each subject and their infant offspring will be followed-up after vaccination and at birth, one, two and seven months of age.
This study has the potential to show clinically significant benefits in the early life of high-risk infants. The additional ear, health and immunisation status assessments offered by this research program are also likely to benefit all participants. This is an affordable vaccine for families and if effective is likely to be a good option for mothers and infants at high risk and could lead to changes to policy related to the use of the vaccine.
Menzies School of Health Research abstract
Menzies School of Health Research
John Matthews Building
Royal Darwin Hospital Campus
PO Box 41096
Casuarina NT 0811
Ph: (08) 8922 8196
Fax: (08) 8927 5187